Minerva Neurosciences Corp (NERV) - Gross Margin

NERV (Minerva Neurosciences Inc) - company brandmark

Minerva Neurosciences is developing scientific partnerships with pharmaceutical giants to create therapies for mental disorders. The gross income metric reflects current profitability trends, where the value 0.00 serves as the baseline indicator. Further growth depends on FDA approval of roluperidone, however, an acute shortage of funds and the risk of regulatory rejection pose a critical threat to the existence of all the company's research.

NERV (Minerva Neurosciences Corp) Gross Profitability history from 07/04/2022 to 11/19/2026

Financial and market metric breakdowns for minervaneurosciences.com (NERV)

- stock value and consensus price forecast:
Mass-produced product of Minerva Neurosciences

Minerva Neurosciences (NERV) protects its market niche through unique patents for roluperidone and stringent FDA regulatory barriers that limit competitor access. Gross margin measures the profit share after deducting direct production costs, allowing investors to evaluate the efficiency of intellectual property monetization by analyzing business resilience through gross profitability trends.

Direct competitors

Return on Gross Profit Biogen Corp|Return on Gross Profit NBIX|Regencell Corp (RGC) - Return on Sales by Gross Profit|Gross Margin AXSM|Return on Gross Profit ACADIA Pharmaceuticals ACAD|Gross Margin XENE (Xenon Pharmaceuticals Inc.)|VKTX (Viking Therapeutics, Inc.) - Gross Profitability Margin|SUPN - Gross Profitability|Catalyst Pharmaceuticals Inc (CPRX) - Return on Gross Profit|DNLI (Denali Corp) - Return on Gross Profit|Gross Profit Margin harmonybiosciences.com (HRMY)|Return on Gross Profit BHVN|Gross Margin Amylyx|Gross Margin TRVI|PRAX (Praxis Corp) - Gross Profit Rate|Gross Margin AVXL (anavex.com)|CBLL: Gross Return on Sales|PRTA - Gross Profitability|ALEC - Gross Margin|Annexon Inc. (ANNX) - Gross Profitability|Return on Gross Profit Omeros Corp|Return on Gross Profit NGNE|ACIU: Gross Profit Rate|Return on Gross Profit VYGR (Voyager Corp)|Return on Gross Profit Neumora NMRA|Gross Profitability Scilex Holding Company, Inc. SCLX|Gross Sales Margin Tevogen Bio Inc.|ACOG - Gross Profitability|Gross Sales Margin Cognition Therapeutics (CGTX)|IKT (Inhibikase Therapeutics) - Return on Gross Profit|Cassava Sciences Inc (SAVA) - Gross Margin|Return on Gross Profit ASRT|Gross Margin coyatherapeutics.com|Gross Margin VTGN|Ovid Therapeutics - Gross Return on Sales|Gross Margin ABOS (Acumen Pharmaceuticals, Inc)|CRVO - Return on Gross Profit|ATHE - Gross Profitability|Return on Sales by Gross Profit clene.com CLNN|PEPG: Gross Margin|Gross Return on Sales JUNS|RLMD (Relmada Corp) - Gross Margin|Annovis Bio Inc (ANVS) - Return on Sales by Gross Profit|Gross Profitability Grace Therapeutics, Inc. (GRCE)|AIFF (Firefly Neuro) - Gross Profit Rate|Gross Profitability Klotho Neurosciences KLTO|NRSN: Gross Return on Sales|RVPH: Return on Gross Profit|MTVA: Gross Profitability|NRXS (NeurAxis Inc) - Return on Gross Profit|Return on Gross Profit Helius Medical Technologies, Inc.|Gross Profitability Passage Bio Inc.|Gross Profit Margin bionomics.com.au NEUP|Gross Margin ATHA|ADXN (Addex Therapeutics Ltd) - Gross Profit Rate|Gross Profitability alzamend.com ALZN|Return on Sales by Gross Profit Cyclerion Therapeutics (CYCN)|Protagenic - Gross Margin|Gross Profit Rate KTTA (Pasithea Therapeutics Corp)|CRGT: Gross Margin|Avenue Therapeutics Inc. (ATXI) - Gross Margin|BCLI (BrainStorm Cell Therapeutics Inc.) - Gross Margin|Gross Margin Cara Therapeutics Inc|Gross Profitability Chromocell Therapeutics (CHRO)|Gross Profit Ratio ELYM|Gross Profitability Intra-Cellular ITCI|LBPH: Gross Return on Sales|MRNS - Gross Profitability|NKGen Biotech, Inc. (NKGN) - Return on Gross Profit|neurobopharma.com (NRBO) - Gross Profitability|SAGE: Gross Profit Ratio|Gross Profitability Synaptogenix, Inc.|Gross Profitability TRVN|Gross Margin VIGL|Gross Margin anewmeds.com (WENA)|Gross Margin CERE (cerevel.com)